Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study).

MLA

Streichart, Lillian, et al. “Tocilizumab in Chronic Active Antibody-Mediated Rejection: Rationale and Protocol of an in-Progress Randomized Controlled Open-Label Multi-Center Trial (INTERCEPT Study).” Trials, vol. 25, no. 1, Mar. 2024, p. 213. EBSCOhost, https://doi.org/10.1186/s13063-024-08020-0.

APA

Streichart, L., Felldin, M., Ekberg, J., Mjörnstedt, L., Lindnér, P., Lennerling, A., Bröcker, V., Mölne, J., Holgersson, J., Daenen, K., Wennberg, L., Lorant, T., & Baid-Agrawal, S. (2024). Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study). Trials, 25(1), 213. https://doi.org/10.1186/s13063-024-08020-0

Chicago

Streichart, Lillian, Marie Felldin, Jana Ekberg, Lars Mjörnstedt, Per Lindnér, Annette Lennerling, Verena Bröcker, et al. 2024. “Tocilizumab in Chronic Active Antibody-Mediated Rejection: Rationale and Protocol of an in-Progress Randomized Controlled Open-Label Multi-Center Trial (INTERCEPT Study).” Trials 25 (1): 213. doi:10.1186/s13063-024-08020-0.